Develop Business Strategies Of The Trends Shaping And Driving Of Benign Prostatic Hyperplasia Therapeutics Market 2024
"The
Latest Research Report OpportunityAnalyzer: Benign Prostatic
Hyperplasia - Opportunity Analysis and Forecast to 2024 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
GlobalData estimates the 2014
sales for the benign prostatic hyperplasia (BPH) therapeutics market
at approximately $2 billion across the 7MM (US, Germany, France,
Italy, Spain, UK and Japan). The US contributed a significant
majority of these sales, generating an estimated $1.15 billion over
the forecast period, ending in 2024. Benign Prostatic Hyperplasia
therapeutics sales in the 7MM are expected to grow to $4.5 billion at
a Compound Annual Growth Rate (CAGR) of 8.23%. The majority of sales
in the 7MM in 2024 will come from the US, which will represent 65% of
the market; with sales in the 5EU corresponding to 24%, while the
remaining 12% in sales is attributable to Japan. The major driver for
this growth across the 7MM will be the launch of NX-1207, a direct
prostatic injection, which represents a first-in-class therapy for
the treatment of moderate-to- severe BPH.
Highlights
Key Questions Answered
- Overall, the greatest unmet need
in the BPH space is the issue with hard to treat symptoms such as
nocturia and the presence of sexual adverse effects that are common
with BPH medications. There are other prominent unmet needs
highlighted by the Key Opinion Leaders (KOLs). What are these? Will
the pipeline drugs fulfil these unmet needs of the market?
- The 10-year forecast period will
mark the launch of three pipeline BPH drugs. How will the sales of
the existing drugs be impacted? Which of the pipeline drugs will have
the highest peak sales at the highest CAGR, and why?
- Four BPH therapies will face
patent expiration during the forecast period resulting in a therapy
area dominated by generics. How will this affect the market size? How
will pharmaceutical companies be affected and how can they hope to
profit in this environment?
Get
Sample Copy of this report @
https://www.marketresearchreports.biz/sample/sample/491290
Key Findings
- The major driver for growth in
the BPH market during the forecast period will be the launch of three
pipeline therapies which each represent an improvement over currently
available medications in their own right. KOLs believe that the
launch of NX-1207, PRX302 and Vesomni will considerably change the
treatment algorithm for patients with BPH.
- There are substantial unmet
needs in the BPH area which need to be addressed. Targeting any of
these unmet needs represents significant opportunities for investment
in the area.
- KOLs believe that BPH is an
underappreciated disease and that there is the potential for
momentous growth in the field.
Scope
- Overview of BPH, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized BPH therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the BPH
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global BPH therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the BPH therapeutics
market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the BPH therapeutics market
in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM BPH
therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology
16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.2 Symptoms and Diagnosis 21
3.3 Quality of Life 25
Send
An Enquiry Request @
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities
28
4.3 Global Trends 28
4.3.1 US 28
4.3.2 5EU 29
4.3.3 Japan 29
4.4 Forecast Methodology 29
4.4.1 Sources Used 30
4.4.2 Sources Not Used 31
4.4.3 Forecast Assumptions and
Methods - Diagnosed Prevalent Cases 32
4.5 Epidemiological Forecast for
BPH (2014-2024) 33
4.5.1 Diagnosed Prevalent Cases of
BPH 33
4.5.2 Age-Specific Diagnosed
Prevalent Cases of BPH 35
4.5.3 Diagnosed Prevalent Cases of
BPH by Severity Using IPSS Criteria 36
4.5.4 Age Standardized Diagnosed
Prevalence of BPH (%) 37
4.6 Discussion 38
4.6.1 Epidemiological Forecast
Insight 38
4.6.2 Limitations of the Analysis
39
4.6.3 Strengths of the Analysis 39
5 Current Treatment Options 40
5.1 Overview 40
5.2 Product Profiles of Major BPH
Brands 41
5.2.1 Flomax 41
5.2.2 Rapaflo 47
5.2.3 Uroxatral 53
5.2.4 Other 1-adrenoceptor
antagonists 58
5.2.5 Finasteride 59
5.2.6 Avodart 66
5.2.7 Jalyn/Duodart 73
5.2.8 Cialis 79
5.2.9 Antimuscarinics 85
5.2.10 Phytotherapy 87
5.2.11 Medical Devices and
Surgical Treatment 88
6 Unmet Needs Assessment and
Oppportunity Analysis 90
6.1 Overview 90
6.2 There are No Effective Drugs
for the Treatment of Nocturia 91
6.2.1 Unmet need 91
6.2.2 Gap Analysis 92
6.2.3 Opportunity 92
6.3 Sexual Adverse Effects
Encountered Frequently in Patients Receiving BPH Medication 93
6.3.1 Unmet need 93
6.3.2 Gap Analysis 94
6.3.3 Opportunity 95
6.4 There is a Lack of Patient
Awareness of BPH 95
6.4.1 Unmet Need 95
6.4.2 Gap Analysis 96
6.4.3 Opportunity 97
6.5 There are No Accurate
Techniques for the Early Detection of BPH 97
6.5.1 Unmet Need 97
6.5.2 Gap Analysis 98
6.5.3 Opportunity 98
6.6 There are No Drugs that Target
the Cause of BPH 99
6.6.1 Unmet Need 99
6.6.2 Gap Analysis 100
6.6.3 Opportunity 100
6.7 Physician Education about BPH
is Poor 100
6.7.1 Unmet Need 100
6.7.2 Gap Analysis 101
6.7.3 Opportunity 102
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment